Table 1 Baseline characteristics
N = 210 | |
|---|---|
Male, n (%) | 155 (73.8) |
Smoking, n (%) | 105 (50) |
Hypertension, n (%) | 91 (43.3) |
Diabetes mellitus, n (%) | 89 (42) |
Dyslipidemia, n (%) | 63 (30) |
Chest pain, n (%) | 88 (42) |
Heart rate > 70 bpm, n (%) | 201 (95) |
Arterial pressure | |
Systolic, mmHg | 115 ± 22 |
diastolic, mmHg | 73 ± 13 |
Congestive heart failure, n (%) | 136 (64.7) |
AF, n (%) | 84 (40) |
NSVT, n (%) | 6 (2.8) |
Ventricular premature beats, n (%) | 64 (30) |
LBBB, n (%) | 60 (28.6) |
LBBB < 120ms, % | 45 |
LBBB [120–130], % | 38.4 |
LBBB [130-150ms], % | 11.6 |
LBBB > 150ms, % | 5 |
Q wave, n (%) | 21 (19) |
Hemoglobin level, g/dl | 12 ± 1 |
Creatinine level, ùmol/l | 97.1 ± 32.4 |
LVEF < 35%, n (%) | 130 (61.9) |
RV dysfunction, n (%) | 21 (10) |
Causes of HFrEF | |
Ischemic cause, n (%) | 97 (46.2) |
Valvular cause, n (%) | 50 (23.8) |
Idiopathic, n (%) | 34 (16.2) |
Hypertensive, n (%) | 29 (13.8) |
ACEi, n (%) | 182 (86,6) |
BB, n (%) | 186 (88,6) |
MRA, n (%) | 75 (35,7) |
Furosemide, n (%) | 210 (100) |
Ivabradine, n (%) | 10 (21) |
SGLT2i, n (%) | 19 (9) |
Sacubitril/Valsartan, n (%) | 31 (15) |
ACEI + BB + MRA + SLGT2i, n (%) | 17 (8.1) |
ACEI + BB + MRA, n (%) | 75(35.7) |
ACEI + BB, n (%) | 164 (78) |
ACEI or BB, n (%) | 30 (14.3) |
CRT-P, n (%) | 10 (4.8) |
CRT-D, n (%) | 6 (2.8) |
ICD, n (%) | 8 (3.8) |